Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens - PubMed (original) (raw)
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens
T C Wu et al. Proc Natl Acad Sci U S A. 1995.
Abstract
The presentation of antigenic peptides by major histocompatibility complex (MHC) class II molecules to CD4+ T cells is critical to the function of the immune system. In this study, we have utilized the sorting signal of the lysosomal-associated membrane protein LAMP-1 to target a model antigen, human papillomavirus 16 E7 (HPV-16 E7), into the endosomal and lysosomal compartments. The LAMP-1 sorting signal reroutes the antigen into the MHC class II processing pathway, resulting in enhanced presentation to CD4+ cells in vitro. In vivo immunization experiments in mice demonstrated that vaccinia containing the chimeric E7/LAMP-1 gene generated greater E7-specific lymphoproliferative activity, antibody titers, and cytotoxic T-lymphocyte activities than vaccinia containing the wild-type HPV-16 E7 gene. These results suggest that specific targeting of an antigen to the endosomal and lysosomal compartments enhances MHC class II presentation and vaccine potency.
Similar articles
- Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Ji H, et al. Hum Gene Ther. 1999 Nov 20;10(17):2727-40. doi: 10.1089/10430349950016474. Hum Gene Ther. 1999. PMID: 10584920 - Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Kang TH, Lee JH, Bae HC, Noh KH, Kim JH, Song CK, Shin BC, Hung CF, Wu TC, Park JS, Kim TW. Kang TH, et al. Immunol Lett. 2006 Aug 15;106(2):126-34. doi: 10.1016/j.imlet.2006.05.004. Epub 2006 May 22. Immunol Lett. 2006. PMID: 16844231 - Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Ling M, Slater LA, Roden RB, Wu TC. Cheng WF, et al. Hum Gene Ther. 2001 Feb 10;12(3):235-52. doi: 10.1089/10430340150218387. Hum Gene Ther. 2001. PMID: 11177561 - Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting.
Hauser H, Chen SY. Hauser H, et al. Methods. 2003 Nov;31(3):225-31. doi: 10.1016/s1046-2023(03)00136-1. Methods. 2003. PMID: 14511955 Review. - Viral inhibition of MHC class II antigen presentation.
Hegde NR, Chevalier MS, Johnson DC. Hegde NR, et al. Trends Immunol. 2003 May;24(5):278-85. doi: 10.1016/s1471-4906(03)00099-1. Trends Immunol. 2003. PMID: 12738423 Review. No abstract available.
Cited by
- Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes.
Lee YH, Bae HC, Noh KH, Song KH, Ye SK, Mao CP, Lee KM, Wu TC, Kim TW. Lee YH, et al. Clin Cancer Res. 2015 Mar 15;21(6):1438-46. doi: 10.1158/1078-0432.CCR-14-1979. Epub 2015 Jan 14. Clin Cancer Res. 2015. PMID: 25589622 Free PMC article. - Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X, Chen SL. Liu DW, et al. J Virol. 2000 Mar;74(6):2888-94. doi: 10.1128/jvi.74.6.2888-2894.2000. J Virol. 2000. PMID: 10684306 Free PMC article. - DC-based cancer vaccines.
Gilboa E. Gilboa E. J Clin Invest. 2007 May;117(5):1195-203. doi: 10.1172/JCI31205. J Clin Invest. 2007. PMID: 17476349 Free PMC article. Review. - SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens.
Gupta V, Tabiin TM, Sun K, Chandrasekaran A, Anwar A, Yang K, Chikhlikar P, Salmon J, Brusic V, Marques ET, Kellathur SN, August TJ. Gupta V, et al. Virology. 2006 Mar 30;347(1):127-39. doi: 10.1016/j.virol.2005.11.042. Epub 2006 Jan 4. Virology. 2006. PMID: 16387339 Free PMC article. - Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.
Chang CL, Ma B, Pang X, Wu TC, Hung CF. Chang CL, et al. Mol Ther. 2009 Aug;17(8):1365-72. doi: 10.1038/mt.2009.118. Epub 2009 May 26. Mol Ther. 2009. PMID: 19471247 Free PMC article.
References
- J Immunol. 1992 Jul 15;149(2):429-37 - PubMed
- Virology. 1989 May;170(1):311-5 - PubMed
- Trends Neurosci. 1989 Oct;12(10):400-6 - PubMed
- Curr Opin Immunol. 1994 Oct;6(5):746-54 - PubMed
- J Cell Biol. 1985 Jul;101(1):85-95 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous